Target Name: BTG4
NCBI ID: G54766
Review Report on BTG4 Target / Biomarker Content of Review Report on BTG4 Target / Biomarker
BTG4
Other Name(s): B-cell translocation gene 4, transcript variant X16 | BTG4 variant X9 | BTG anti-proliferation factor 4, transcript variant X20 | OOMD8 | B-cell translocation gene 4, transcript variant X9 | B-cell translocation gene 4, transcript variant X11 | B-cell translocation gene 4, transcript variant X14 | B-cell translocation gene 4, transcript variant X21 | BTG anti-proliferation factor 4, transcript variant X11 | BTG4 variant X1 | BTG4_HUMAN | BTG anti-proliferation factor 4, transcript variant X6 | Protein BTG4 (isoform 1) | B-cell translocation gene 4, transcript variant X25 | B-cell translocation gene 4, transcript variatn X12 | B-cell translocation gene 4, transcript variant X1 | BTG4 variant X18 | B-cell translocation gene 4, transcript variant X8 | B-cell translocation gene 4, transcript variant X6 | BTG4 variant X10 | B-cell translocation gene 4, transcript variant X17 | BTG anti-proliferation factor 4 | B-cell translocation gene 4, transcript variant X7 | BTG4 variant X20 | BTG anti-proliferation factor 4, transcript variant X13 | BTG4 variant X6 | B-cell translocation gene 4, transcript variant X5 | PC3B | BTG4 variant X7 | Protein PC3b | BTG4 variant X21 | BTG anti-proliferation factor 4, transcript variant 1 | BTG anti-proliferation factor 4, transcript variant X7 | BTG anti-proliferation factor 4, transcript variant X12 | B-cell translocation gene 4, transcript variant X2 | BTG4 variant X2 | BTG4 variant X13 | Protein BTG4 (isoform X2) | Protein BTG4, transcript variant X14 | B-cell translocation gene 4, transcript variant X18 | BTG4 variant X11 | protein PC3b | BTG family member 4 | BTG4 variant X12 | BTG4 variant X16 | Protein BTG4 isoform X4 | B-cell translocation gene 4 | Protein BTG4 | APRO3 | BTG anti-proliferation factor 4, transcript variant X10 | BTG4 variant X14 | Protein BTG4 isoform X2 | BTG4 variant X25 | BTG4 variant X17 | BTG4 variant X8 | B-cell translocation gene 4, transcript variant X10 | B-cell translocation gene 4, transcript variant X13 | BTG4 variant 1 | BTG4 variant X5

BTG4: A Drug Target / Disease Biomarker

BTG4 (Bcl-2-associated gene 4) is a protein that is expressed in various tissues and cells throughout the body. It is a member of the Bcl-2 gene family, which is known for its role in regulating cell survival and apoptosis (programmed cell death) programs. BTG4 has been identified as a potential drug target and has been shown to play a role in a variety of biological processes, including cell proliferation, apoptosis, and inflammation.

The Bcl-2 gene family consists of four genes: Bcl-2, Bcl-3, Bcl-4, and Bcl-5. These genes encode for proteins that contain a characteristic Bcl-2 domain, which is a conserved protein that is involved in the regulation of apoptosis. The Bcl-2 domain is a transmembrane protein that contains a variety of pro-apoptotic and anti-apoptotic effects.

BTG4 is a 120 amino acid protein that is expressed in various tissues and cells, including brain, spinal cord, and peripheral tissues. It is a protein that is highly conserved and has a calculated molecular weight of 11.9 kDa. BTG4 is typically expressed in a cell-type-specific manner and is shown to be involved in the regulation of cell survival and apoptosis.

One of the key functions of BTG4 is its role in the regulation of apoptosis. Apoptosis is a programmed cell death that is controlled by a variety of factors, including the expression of pro-apoptotic and anti-apoptotic proteins. BTG4 is involved in the regulation of apoptosis by promoting the expression of pro-apoptotic proteins and inhibiting the expression of anti-apoptotic proteins.

For example, BTG4 has been shown to promote the expression of Bax, a protein that is involved in the regulation of apoptosis. Bax is a pro-apoptotic protein that is involved in the execution of cell death. In addition, BTG4 has been shown to inhibit the expression of survivin, an anti-apoptotic protein that is involved in the regulation of cell survival.

BTG4 is also involved in the regulation of cell proliferation. It has been shown to play a role in the regulation of cell cycle progression and the number of cell divisions that a cell can undergo. In addition, BTG4 is involved in the regulation of cell adhesion and the formation of tight junctions, which are important for the proper functioning of tissues and organs.

In addition to its role in the regulation of apoptosis and cell proliferation, BTG4 is also involved in the regulation of inflammation. It has been shown to play a role in the regulation of immune cell function and the production of inflammatory cytokines.

BTG4 has also been shown to be involved in a variety of signaling pathways. For example, it has been shown to be involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cell survival and metabolism.

Given its role in the regulation of apoptosis, cell proliferation, and inflammation, BTG4 is a potential drug target. Studies have shown that BTG4 has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In addition to its potential as a drug target, BTG4 has also been shown to have a variety of potential therapeutic applications. For example, it has been shown to be involved in the regulation of cancer cell survival and has been shown to be a potential inhibitor of cancer cell proliferation.

In addition, BTG4 has also been shown to have a variety of potential applications in the field of neurodegenerative diseases. For example, it has been shown to play

Protein Name: BTG Anti-proliferation Factor 4

Functions: Adapter protein that bridges CNOT7, a catalytic subunit of the CCR4-NOT complex, to EIF4E (By similarity). Facilitates maternal mRNAs decay during the maturation of oocytes and in the fertilized egg, and is required for the maternal-zygotic transition (MZT), zygotic cleavage and initiation of embryonic development (PubMed:32502391)

The "BTG4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BTG4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

BTK | BTLA | BTN1A1 | BTN2A1 | BTN2A2 | BTN2A3P | BTN3A1 | BTN3A2 | BTN3A3 | BTNL10P | BTNL2 | BTNL3 | BTNL8 | BTNL9 | BTRC | BUB1 | BUB1B | BUB1B-PAK6 | BUB3 | BUD13 | BUD23 | BUD31 | Butyrophilin | Butyrophilin subfamily 3 member A (BTN3A) | BVES | BVES-AS1 | BYSL | BZW1 | BZW1-AS1 | BZW1P2 | BZW2 | C-C chemokine receptor | C10orf105 | C10orf113 | C10orf120 | C10orf126 | C10orf143 | C10orf53 | C10orf55 | C10orf62 | C10orf67 | C10orf71 | C10orf71-AS1 | C10orf82 | C10orf88 | C10orf88B | C10orf90 | C10orf95 | C10orf95-AS1 | C11orf16 | C11orf21 | C11orf24 | C11orf40 | C11orf42 | C11orf52 | C11orf54 | C11orf58 | C11orf65 | C11orf68 | C11orf71 | C11orf80 | C11orf86 | C11orf87 | C11orf91 | C11orf96 | C11orf97 | C11orf98 | C12orf29 | C12orf4 | C12orf40 | C12orf42 | C12orf43 | C12orf50 | C12orf54 | C12orf56 | C12orf57 | C12orf60 | C12orf74 | C12orf75 | C12orf76 | C13orf42 | C13orf46 | C14orf119 | C14orf132 | C14orf178 | C14orf180 | C14orf28 | C14orf39 | C14orf93 | C15orf32 | C15orf39 | C15orf40 | C15orf48 | C15orf61 | C15orf62 | C16orf46 | C16orf54 | C16orf74 | C16orf78 | C16orf82